241 related articles for article (PubMed ID: 26337086)
1. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death.
Catanzaro D; Gaude E; Orso G; Giordano C; Guzzo G; Rasola A; Ragazzi E; Caparrotta L; Frezza C; Montopoli M
Oncotarget; 2015 Oct; 6(30):30102-14. PubMed ID: 26337086
[TBL] [Abstract][Full Text] [Related]
2. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
Montopoli M; Bellanda M; Lonardoni F; Ragazzi E; Dorigo P; Froldi G; Mammi S; Caparrotta L
Curr Cancer Drug Targets; 2011 Feb; 11(2):226-35. PubMed ID: 21158717
[TBL] [Abstract][Full Text] [Related]
3. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
4. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
5. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.
Wangpaichitr M; Wu C; Li YY; Nguyen DJM; Kandemir H; Shah S; Chen S; Feun LG; Prince JS; Kuo MT; Savaraj N
Oncotarget; 2017 Jul; 8(30):49275-49292. PubMed ID: 28525376
[TBL] [Abstract][Full Text] [Related]
6. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
7. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
8. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
9. Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS.
Qu X; Sheng J; Shen L; Su J; Xu Y; Xie Q; Wu Y; Zhang X; Sun L
PLoS One; 2017; 12(3):e0173712. PubMed ID: 28301876
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells.
Hirama M; Isonishi S; Yasuda M; Ishikawa H
Oncol Rep; 2006 Nov; 16(5):997-1002. PubMed ID: 17016583
[TBL] [Abstract][Full Text] [Related]
11. Mitochondria Participate in Chemoresistance to Cisplatin in Human Ovarian Cancer Cells.
Zampieri LX; Grasso D; Bouzin C; Brusa D; Rossignol R; Sonveaux P
Mol Cancer Res; 2020 Sep; 18(9):1379-1391. PubMed ID: 32471883
[TBL] [Abstract][Full Text] [Related]
12. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
13. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.
Talarico T; Cullinane CM; Gray PJ; Webster LK; Deacon GB; Phillips DR
Anticancer Drug Des; 2001; 16(2-3):135-41. PubMed ID: 11962511
[TBL] [Abstract][Full Text] [Related]
14. PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.
Shen L; Zhou L; Xia M; Lin N; Ma J; Dong D; Sun L
Exp Cell Res; 2021 Jan; 398(1):112369. PubMed ID: 33220258
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance.
Leung EL; Fraser M; Fiscus RR; Tsang BK
Br J Cancer; 2008 Jun; 98(11):1803-9. PubMed ID: 18506185
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
18. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.
Feng Q; Li X; Sun W; Sun M; Li Z; Sheng H; Xie F; Zhang S; Shan C
Biochem Pharmacol; 2020 Aug; 178():114092. PubMed ID: 32535103
[TBL] [Abstract][Full Text] [Related]
19. Metabolic vulnerability of cisplatin-resistant cancers.
Obrist F; Michels J; Durand S; Chery A; Pol J; Levesque S; Joseph A; Astesana V; Pietrocola F; Wu GS; Castedo M; Kroemer G
EMBO J; 2018 Jul; 37(14):. PubMed ID: 29875130
[TBL] [Abstract][Full Text] [Related]
20. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
Sun H; Wang H; Wang X; Aoki Y; Wang X; Yang Y; Cheng X; Wang Z; Wang X
Theranostics; 2020; 10(15):6928-6945. PubMed ID: 32550913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
